FTC, Amgen/Horizon told to push for in-house trial delay

The Federal Trade Commission’s internal judge has encouraged Amgen, Horizon Therapeutics and agency staff to go ahead with plans to ask the commissioners to delay the administrative case against the drugmakers’ merger.

Unlock unlimited access to all Global Competition Review content